Friday, July 10, 2026

Drug profile · INN

sitagliptin, metformin hydrochloride

sitagliptin, metformin hydrochloride (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — sitagliptin, metformin hydrochloride
US status
approved
Class
Route
Patents
0
Programs
2
Data quality
0.81

Quick answer

sitagliptin, metformin hydrochloride (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

Key facts

INN sitagliptin, metformin hydrochloride
Brand SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Formulation TABLET, EXTENDED RELEASE

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Intervention A Fluoxetine Hydrochloride (HCl) Phase 2 · Adaptive Biotechnologies · Post Traumatic Stress Disorder
  2. Intervention B Vilazodone Hydrochloride (HCl) Phase 2 · Adaptive Biotechnologies · Post Traumatic Stress Disorder

Frequently asked questions

What is sitagliptin, metformin hydrochloride?

sitagliptin, metformin hydrochloride (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

What is the brand name for sitagliptin, metformin hydrochloride?

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is a marketed brand name for sitagliptin, metformin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sitagliptin, metformin hydrochloride?

sitagliptin, metformin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.